Biodexa Pharmaceuticals Stock (NASDAQ:BDRX)


RevenueOwnershipFinancialsChart

Previous Close

$0.28

52W Range

$0.23 - $8.81

50D Avg

$0.51

200D Avg

$1.09

Market Cap

$69.11K

Avg Vol (3M)

$1.52M

Beta

1.43

Div Yield

-

BDRX Company Profile


Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

21

IPO Date

Dec 07, 2015

Website

BDRX Performance


BDRX Financial Summary


Dec 23Dec 22Dec 21
Revenue£381.00K£699.00K£578.00K
Operating Income£-8.01M£-8.93M£-7.00M
Net Income£-7.08M£-7.66M£-5.46M
EBITDA£-7.65M£-8.76M£-6.79M
Basic EPS-£-619.72£-542.31
Diluted EPS-£-619.72£-542.31

Fiscal year ends in Dec 23 | Currency in GBP

Latest Earnings Call Transcripts


Q2 21Sep 20, 21 | 3:44 PM
Q2 20Sep 10, 20 | 5:00 PM
Q2 15Aug 13, 15 | 5:00 PM